|
**Overview**: Pernicious Anemia Panel**Introduction**: The Pernicious Anemia Panel is a diagnostic tool designed to screen for pernicious anemia using serum samples. In India, pernicious anemia (autoimmune gastritis, intrinsic factor deficiency) affects ~1-2 percent of elderly, causing megaloblastic anemia and subacute combined degeneration due to vitamin B12 malabsorption. High morbidity from under-testing in rural/low-SES elderly with neuropathy, glossitis, or macrocytic anemia, limited autoantibody labs, delayed B12 injections leading to irreversible neurological damage. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs spectrophotometry for vitamin B12, folate, intrinsic factor Ab, and parietal cell Ab over 1-2 days with high accuracy, valuable for confirming autoimmune etiology. This diagnostic falls under anemia screening and targets elderly patients with macrocytic anemia or neuropathy, addressing accurate detection to guide lifelong B12 replacement. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise autoimmune assessment and reducing neurological complications. Its serum-based approach ensures reliable antibody and vitamin measurement.**Other Names**: Pern Anemia Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: Intrinsic factor/parietal cell Ab panel standard; in India, used in hematology.**Purpose**: The test assesses 4 parameters including vitamin B12 to guide pernicious anemia screening, detect deficiency/autoantibodies, inform B12 therapy.**Test Parameters**: 1. Vitamin B12, 2. Folate, 3. Intrinsic Factor Ab, 4. Parietal Cell Ab.**Pretest Condition**: No fasting required; patients should have macrocytic anemia.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on neuropathy, glossitis, diet.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated pernicious anemia including neuropathy, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or recent supplementation can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Low B12 + positive intrinsic factor/parietal cell Ab confirms pernicious anemia, necessitating specialist input.**Specialist Consultation**: Hematologists or neurologists should be consulted for management.**Additional Supporting Tests**: Schilling test (rare), MMA/homocysteine for confirmation.**Test Limitations**: Antibody sensitivity variable; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Anemia Studies India 2023. |
